Implantation disturbance studies with linear alkylbenzene sulphonate in mice.

Abstract

Problems were evaluated in ICR mice concerning the implantation disturbance of linear alkylbenzene sulphonate (LAS). An experiment was made to determine the incidence of implantation disturbance, distribution in the body organs, and mutagenicity of LAS administered in early pregnancy. Approximately 14, 70, or 350 mg/kg of LAS was administered orally once on day 3 of gestation or once daily from day 1 to day 3 of gestation, for 3 consecutive days. There was no significant difference in the incidence of implantation disturbance between any treated group and the control group. A single dose of 350 mg/kg of LAS was administered orally to investigate the distribution of LAS in the liver, kidney, reproductive organs (uterus and ovaries), and gastrointestinal tract 4 and 8 hr after administration on day 3 of gestation. In the liver, C10–11 components were more rapidly metabolized and C12–13 components remained unchanged. The LAS was not detected in the reproductive organs. On day 3 of gestation, LAS was administered in a single oral dose of 2 mg/mouse and on day 18 of gestation, each animal was sacrificed. On day 17 of gestation, each animal received a subcutaneous dose of 1, 2 or 10 mg/mouse and was sacrificed 24 hr later to test the mutagenicity of LAS using the micronucleusin vivo test. There was no difference among treated groups in the incidence of polychromatic erythrocytes with micronuclei in the maternal bone marrow and the fetal liver and blood. No mutagenicity was found in any of the groups.